<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446770</url>
  </required_header>
  <id_info>
    <org_study_id>HAL-0127</org_study_id>
    <nct_id>NCT01446770</nct_id>
  </id_info>
  <brief_title>Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181</brief_title>
  <official_title>A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halscion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halscion, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the initial safety and efficacy of MF-4181, a&#xD;
      hydrogel scaffold, in the reduction of the volume, appearance, and/or symptoms associated&#xD;
      with keloid scarring in subjects undergoing surgical revision of keloid scars.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device safety</measure>
    <time_frame>6 months</time_frame>
    <description>Device safety is defined as the incidence of device related adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluations of cosmesis, induration, erythema and pigmentation will be evaluated by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Volume and linear measurements will be taken by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Subject evaluation of cosmesis, pain, tenderness, itching and scar satisfaction will be obtained.</description>
  </secondary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Keloid</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrogel scaffold (MF-4181)</intervention_name>
    <description>Following surgical removal of the ear keloid, the incision will be treated with MF-4181.</description>
    <other_name>Hydrogel scaffold</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects 15 to 50 years of age each having at least one keloid scar on&#xD;
             the ear. (If both ears have keloids, both ears may be treated with E-Matrix).&#xD;
&#xD;
          -  Keloids that have not undergone more than two surgical revisions (laser, cryotherapy&#xD;
             or surgery)&#xD;
&#xD;
          -  Keloids that have been present for ≥ 1 year.&#xD;
&#xD;
          -  The keloid must measure ≥ 0.5 cm and not extend onto other portions of the head, neck,&#xD;
             or face.&#xD;
&#xD;
          -  Able and willing to give written informed consent. (Age 15-17 must have written&#xD;
             informed consent of legal guardian).&#xD;
&#xD;
          -  Willing to comply with the follow up schedule for a minimum of 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with history of prior treatment at the study site or prior treatment of the&#xD;
             keloid in the previous 6 weeks.&#xD;
&#xD;
          -  Pregnant or planning to become pregnant during the course of the study.&#xD;
&#xD;
          -  Heart disease or history of congestive heart failure.&#xD;
&#xD;
          -  Advanced or poorly controlled diabetes.&#xD;
&#xD;
          -  Current or history of heavy smoking (i.e., 10 pack years)&#xD;
&#xD;
          -  Active local infection at the treatment site and/or systemic infection.&#xD;
&#xD;
          -  History of or active central nervous system disease.&#xD;
&#xD;
          -  History of fever, migraine headaches, and/or recurrent upper respiratory infection.&#xD;
&#xD;
          -  Active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus,&#xD;
             polyarthritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic&#xD;
             purpura.&#xD;
&#xD;
          -  Unwilling or unable to return for follow-up visits.&#xD;
&#xD;
          -  Unwilling to refrain from use of any other scar treatment therapy/scar improving&#xD;
             product, during the study, including steroid injections.&#xD;
&#xD;
          -  Regular, continuous use of systemic corticosteroid therapy or topical corticosteroid&#xD;
             use in the area to be treated.&#xD;
&#xD;
          -  Current participation or participation within the last 3 months in the study of an&#xD;
             investigational drug, device, or biologic.&#xD;
&#xD;
          -  Unable or unwilling to follow post-operative instructions.&#xD;
&#xD;
          -  Known hypersensitivity to MF-4181, collagen, dextran, or any of its constituent&#xD;
             materials.&#xD;
&#xD;
          -  Known hypersensitivities to animal-based products&#xD;
&#xD;
          -  Previous participation in this study to avoid multiple enrollments of an individual&#xD;
             subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srikanth Garikaparthi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Nassau</city>
        <country>Bahamas</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bahamas</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 2, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

